IL97571A - Preparations for the treatment of polycystic ovary disease - Google Patents

Preparations for the treatment of polycystic ovary disease

Info

Publication number
IL97571A
IL97571A IL9757191A IL9757191A IL97571A IL 97571 A IL97571 A IL 97571A IL 9757191 A IL9757191 A IL 9757191A IL 9757191 A IL9757191 A IL 9757191A IL 97571 A IL97571 A IL 97571A
Authority
IL
Israel
Prior art keywords
administered
administration
higfbp
estrogen
fsh
Prior art date
Application number
IL9757191A
Other languages
English (en)
Hebrew (he)
Other versions
IL97571A0 (en
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909005958A external-priority patent/GB9005958D0/en
Priority claimed from GB909011823A external-priority patent/GB9011823D0/en
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of IL97571A0 publication Critical patent/IL97571A0/xx
Publication of IL97571A publication Critical patent/IL97571A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL9757191A 1990-03-16 1991-03-15 Preparations for the treatment of polycystic ovary disease IL97571A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909005958A GB9005958D0 (en) 1990-03-16 1990-03-16 Treatment of polycystic ovarian disease
GB909011823A GB9011823D0 (en) 1990-05-25 1990-05-25 Treatment of polycystic ovarian disease

Publications (2)

Publication Number Publication Date
IL97571A0 IL97571A0 (en) 1992-06-21
IL97571A true IL97571A (en) 1999-11-30

Family

ID=26296796

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9757191A IL97571A (en) 1990-03-16 1991-03-15 Preparations for the treatment of polycystic ovary disease

Country Status (11)

Country Link
EP (1) EP0472725B1 (de)
JP (1) JP3112172B2 (de)
AT (1) ATE153345T1 (de)
AU (1) AU647138B2 (de)
CA (1) CA2054686C (de)
DE (1) DE69126180T2 (de)
DK (1) DK0472725T3 (de)
ES (1) ES2102397T3 (de)
GR (1) GR3024225T3 (de)
IL (1) IL97571A (de)
WO (1) WO1991014704A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492177B1 (en) * 1990-03-16 2002-12-10 Applied Research Systems Ars Holding Nv Kit for use in treatment of polycystic ovarian disease
US6489288B1 (en) * 1990-03-16 2002-12-03 Applied Research Systems Ars Holding Treatment of polycystic ovarian disease
FI94181C (fi) * 1992-06-29 1995-07-25 Medix Biochemica Ab Oy Diagnostinen menetelmä synnytysajankohdan ennustamiseksi sekä siihen käytettävä reagenssipakkaus
US5681817A (en) 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
DE19815060A1 (de) * 1998-04-03 1999-10-14 Jenapharm Gmbh Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie
GB0307777D0 (en) 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK272789D0 (da) * 1989-06-02 1989-06-02 Novo Nordisk As Fremgangsmaade og praeparat til behandling af infertilitet

Also Published As

Publication number Publication date
CA2054686C (en) 2007-09-25
CA2054686A1 (en) 1991-09-17
IL97571A0 (en) 1992-06-21
ES2102397T3 (es) 1997-08-01
WO1991014704A3 (en) 1991-11-14
DE69126180T2 (de) 1997-08-28
ATE153345T1 (de) 1997-06-15
JP3112172B2 (ja) 2000-11-27
EP0472725B1 (de) 1997-05-21
WO1991014704A2 (en) 1991-10-03
AU7879791A (en) 1991-10-21
GR3024225T3 (en) 1997-10-31
DE69126180D1 (de) 1997-06-26
JPH05501119A (ja) 1993-03-04
AU647138B2 (en) 1994-03-17
DK0472725T3 (da) 1997-11-03
EP0472725A1 (de) 1992-03-04

Similar Documents

Publication Publication Date Title
Quaas et al. Pharmacology of medications used for ovarian stimulation
US7405197B2 (en) Use of hCG in controlled ovarian hyperstimulation
Van der Meer et al. Endocrinology: Follicle stimulating hormone (FSH) dynamics of low dose step-up ovulation induction with FSH in patients with polycystic ovary syndrome
EP0472725B1 (de) Behandlung polyzystischer ovarkrankheit
EP1425033B1 (de) Verwendung von humanem choriongonadotropin (hcg) und luteinisierendem hormon (lh) zur regulierten hyperstimulation der eierstöcke
TAPANAINEN et al. Short and long term effects of growth hormone on circulating levels of insulin-like growth factor-I (IGF-I), IGF-binding protein-1, and insulin: A placebo controlled study
US6489288B1 (en) Treatment of polycystic ovarian disease
HRP20040070A2 (en) Use of lh in controlled ovarian hyperstimulation
Parker et al. Pituitary hormones and their hypothalamic releasing hormones
US6492177B1 (en) Kit for use in treatment of polycystic ovarian disease
Kenigsberg et al. Induction of ovulation in primate models
Giustina et al. Role of galanin in the regulation of somatotrope and gonadotrope function in young ovulatory women
Siler-Khodr et al. Dose-related actions of GnRH II analog in the cycling rhesus monkey
Akagbosu The use of GnRH agonists and antagonists in infertility
Hugues et al. Endocrine characteristics of ART cycles
AU2002324183B2 (en) Use of hCG and LH in controlled ovarian hyperstimulation
Quaas et al. Best Practice & Research Clinical Endocrinology & Metabolism
Akagbosu et al. The use of gonadotropin releasing hormone agonists and antagonists in infertility
Shoham et al. Drugs used for ovarian stimulation: Clomiphene citrate, aromatase inhibitors, metformin, gonadotropins, gonadotropin-releasing hormone analogs, and recombinant gonadotropins
Venturini et al. Use of combined exogenous gonadotropins and pulsatile gonadotropin-releasing hormone in patients with polycystic ovarian disease: a new approach to induction of ovulation
Fraser Risk of luteal phase inadequacy after GnRH agonist-induced ovulation
Baird Manipulation of the ovarian cycle
Shoham Drugs use for controlled ovarian stimulation: clomiphene citrate, aromatase inhibitors, gonadotropins, and gonadotropin-releasing hormone analogs
AU2002324183A1 (en) Use of hCG and LH in controlled ovarian hyperstimulation
AU2002324179A1 (en) Use of hCG in controlled ovarian hyperstimulation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees